# Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism

> **NCT06465108** · PHASE2 · COMPLETED · sponsor: **MBX Biosciences** · enrollment: 64 (actual)

## Conditions studied

- Hypoparathyroidism

## Interventions

- **DRUG:** MBX 2109
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06465108
- **Lead sponsor:** MBX Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-08
- **Primary completion:** 2025-05-23
- **Final completion:** 2025-06-04
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06465108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06465108, "Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06465108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*